Modulation of the cGMP-dependent protein kinase 1-phosphodiesterase (cGMP-cGK1-PDE) signalling pathway may be renoprotective and could lead to the development of innovative therapeutic approaches for chronic kidney disease. This evidence concerns the gene PRKG1 and chronic kidney disease.